Marché des fournitures pour essais cliniques en Asie-Pacifique – Tendances et prévisions du secteur jusqu’en 2029

Demande de table des matières Demande de table des matières Parler à un analysteParler à un analyste Acheter maintenantAcheter maintenant Renseignez-vous avant d'acheterRenseignez-vous avant Exemple de rapport gratuitExemple de rapport gratuit

Marché des fournitures pour essais cliniques en Asie-Pacifique – Tendances et prévisions du secteur jusqu’en 2029

  • Healthcare
  • Publish Reports
  • Mar 2022
  • Asia-Pacific
  • 350 Pages
  • Nombre de tableaux : 70
  • Nombre de figures : 35

Asia Pacific Clinical Trial Supplies Market

Taille du marché en milliards USD

TCAC :  % Diagram

Diagram Période de prévision
2023 –2029
Diagram Taille du marché (année de référence)
MILLIONS DE DOLLARS AMÉRICAINS
Diagram Taille du marché (année de prévision)
Dollars américains 1,021.35
Diagram TCAC
%
Diagram Principaux acteurs du marché
  • Movianto
  • Sharp
  • Thermo Fisher Scientific
  • Catalent
  • and more

>Marché des fournitures d'essais cliniques en Asie-Pacifique, par services (stockage, fabrication, emballage, étiquetage et distribution), phase clinique (phase III, phase II, phase IV, phase I), utilisations thérapeutiques (oncologie, maladies cardiovasculaires, dermatologie, troubles métaboliques, maladies infectieuses, maladies respiratoires, troubles du SNC et mentaux, troubles sanguins , autres), utilisateur final (organismes de recherche sous contrat, sociétés pharmaceutiques et biotechnologiques), tendances de l'industrie et prévisions jusqu'en 2029.

Marché des fournitures pour essais cliniques en Asie-Pacifique

Analyse et perspectives du marché : marché des fournitures pour essais cliniques en Asie-Pacifique

Le marché des fournitures pour essais cliniques en Asie-Pacifique devrait connaître une croissance du marché au cours de la période de prévision de 2022 à 2029. Data Bridge Market Research analyse que le marché croît avec un TCAC de 9,2 % au cours de la période de prévision de 2022 à 2029 et devrait atteindre 1 021,35 millions USD d'ici 2029. Les principaux facteurs à l'origine de la croissance du marché des fournitures pour essais cliniques sont l'augmentation de la demande d'essais cliniques dans le monde entier, l'augmentation de l'incidence des maladies, les fonds gouvernementaux pour les investissements en R&D et le développement de nouveaux traitements tels que la médecine personnalisée, ce qui conduit le marché des fournitures pour essais cliniques à croître à l'avenir.

L' essai clinique est une étude de recherche qui détermine si une stratégie, un traitement ou un dispositif médical est sûr, efficace et utile pour l'homme. Ces études aident à déterminer quelles approches médicales sont les plus adaptées à certaines maladies. Un essai clinique fournit les meilleures données pour la prise de décision en matière de soins de santé.

L'objectif des essais cliniques est d'étudier des normes scientifiques strictes. Ces normes protègent les patients et contribuent à produire des résultats d'étude fiables.

Les essais cliniques constituent la dernière étape du développement d'un médicament dans le cadre d'un processus de recherche long et minutieux mené par des scientifiques ou des chercheurs sur une maladie particulière, qu'il s'agisse d'un médicament ou d'un dispositif médical. Le processus de développement d'un médicament commence souvent dans un laboratoire, où les scientifiques développent et testent d'abord de nouvelles idées liées au traitement de la maladie.

Le rapport sur le marché des fournitures d'essais cliniques en Asie-Pacifique fournit des détails sur la part de marché, les nouveaux développements et l'analyse du pipeline de produits, l'impact des acteurs du marché national et local, analyse les opportunités en termes de poches de revenus émergentes, de changements dans la réglementation du marché, d'approbations de produits , de décisions stratégiques, de lancements de produits, d'expansions géographiques et d'innovations technologiques sur le marché. Pour comprendre l'analyse et le scénario du marché, contactez-nous pour un briefing d'analyste, notre équipe vous aidera à créer une solution d'impact sur les revenus pour atteindre votre objectif souhaité.

Rapport métrique

Détails

Période de prévision

2022 à 2029

Année de base

2021

Années historiques

2020 (personnalisable de 2019 à 2014)

Unités quantitatives

Chiffre d'affaires en millions USD, prix en USD

Segments couverts

By Services ( Storage, Manufacturing, Packaging and labelling and Distribution), Clinical Phase ( Phase III, Phase II, Phase IV, Phase I), Therapeutic Uses (Oncology, Cardiovascular Diseases, Dermatology, Metabolic Disorders, Infectious Diseases, Respiratory Diseases, CNS And Mental Disorders, Blood Disorders, Others), By End User( Contract Research Organizations, Pharmaceutical And Biotechnology Companies)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

Movianto (U.S.), Sharp (U.S.),Thermo Fisher Scientific Inc.,(U.S.), Catalent, Inc (U.S.), PCI Pharma Services (U.S.), Almac Group (U.K.), PAREXEL International Corporation (U.S.), Bionical Ltd. (U.K.), Alium Medical Limited (U.K.), Myonex (U.K.), Clinigen Group plc (U.K.), Ancillare, LP (U.S.), SIRO Clinpharm (India) CLINICAL SUPPLIES MANAGEMENT HOLDINGS, INC. (U.S.) Biocair (U.K.) and among others.

Clinical Trial Supplies Market Dynamics

Drivers

  • Rising Demand for Clinical Trial Worldwide

The rising demand for clinical trial has been 82% alone in developing countries such as North America, Europe, and Asia. These drugs are available in the market after clinical trial, so all the companies mostly carry out clinical trial depending on the type of drug or device machine. and hence act as a major driver that will result in the expansion of the growth rate of the treatment market.

  • Increasing Incidence of Chronic Diseases

The high prevalence of chronic diseases due to the rapidly increasing population and infections among people can be seen globally. These diseases contribute a major role in the clinical trial field for the development of drugs. The drug has to pass all the standard clinical phase to be available before human consumption. Thus, to treat these chronic diseases for humans, the drug has to be safe.

  • Government Funds in R&D Investments

The instruments, workforce, medical management in case of harm to researchers, insurance, transportation, ethics committee fee, data processing, and other consumables lead to major cost involvement in clinical trial. Clinical trial are the evaluation of diseases prevention and treatment ideas will further enhance the growth of treatment market.

Opportunities

  • Increasing new drug development trial in emerging countries

Clinical trial for drug efficacy is the primary key for drugs development for diseases treatment before launching in the market for human consumption. Additionally, the new drugs have to meet license extensions and international standards before selling and distribution. Increasing the prevalence and incidence of diseases and the rise in the patient’s numbers are the factors leading to emerging trends of clinical trial for drug development in developing countries over the past period.

Also, Governments in emerging markets (China, Brazil, Russia, India, and South Africa) reform public healthcare and grant more accessible access to medicine. These two factors working in unison mean greater freedom for market developments and increased innovation in clinical research in emerging markets.

Restraints/Challenges

Adverse drug reactions are the unwanted or harmful effects that can be experienced after the administration of a drug under normal conditions of use in humans. The drug reactions generally occur in jaundice, anaemia, rashes and lead to a decrease in the white blood cell count, damaged kidney, and nerve injury that caused impaired vision or hearing.

Many of the adverse effects may be ascertained from physical examinations during the clinical phase of testing. Thus, reporting adverse effects during clinical trial is the major leading restraints factor for the supplies market. Despite high time and cost investments for developing biologics and new drugs, it is estimated that lower procedure time and rate for approval of drug is creating a biggest challenge for the market, which may hamper the market growth.

This clinical trial supplies market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on clinical trial supplies market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

  • In February 2022, Catalent Inc. announced that the company has expanded the capacity for temperature-controlled storage and distribution of clinical supplies across China. This lead to increase in Clinical Supply for optimize development, launch and better treatments in different morbidities as well as secondary packaging capabilities

Marché des fournitures pour essais cliniques en Asie-Pacifique

Asia-Pacific Clinical Trial Supplies Market Scope

Asia-Pacific clinical trial supplies market is categorized based on services, clinical phase, therapeutic uses and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Service

  • Manufacturing
  • Distribution
  • Storage
  • Packaging and Labelling

On the basis of services the Asia-Pacific clinical trial supplies market is segmented into manufacturing, distribution, storage, and packaging and labelling.

Clinical Phase

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

On the basis of clinical phase the Asia-Pacific clinical trial supplies market is segmented into phase I, phase II, phase III and phase IV.

Therapeutic Uses

  • Oncology
  • CNS
  • Mental Disorders
  • Cardiovascular Diseases
  • Infectious Diseases 
  • Respiratory Diseases
  • Blood Disorder
  • Dermatology
  • Others

On the basis of therapeutic uses, the Asia-Pacific clinical trial supplies market is segmented into oncology, CNS and mental disorders, cardiovascular diseases, infectious disease, respiratory diseases, metabolic disorders, blood disorders, dermatology and others.

End User

  • Contract research organization
  • Pharmaceutical and biotechnology companies

On the basis of end user, the Asia-Pacific clinical trial supplies market is segmented into contract research organizations and pharmaceutical and biotechnology companies.

Clinical Trial Supplies Market Regional Analysis/Insights

The Asia-Pacific Clinical trial supplies market is further segmented into major countries such as Japan, China, South Korea, India, Australia, Singapore, Indonesia, Thailand, Malaysia, Philippines, rest of Asia-Pacific.

India dominates the Asia-Pacific clinical trial supplies market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period of 2022-2029. This is due to the increasing patient pool, rising investment in the healthcare sector and growing government support in this region

The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of global brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Asia-Pacific Clinical Trial Supplies Market Share Analysis

Le paysage concurrentiel du marché des fournitures pour essais cliniques en Asie-Pacifique fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement de produits, les pipelines d'essais de produits, les approbations de produits, les brevets, la largeur et l'étendue du produit, la domination des applications, la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché des fournitures pour essais cliniques.

Français Les principaux acteurs de premier plan opérant sur le marché des fournitures d'essais cliniques en Asie-Pacifique sont Movianto (États-Unis), Sharp (États-Unis), Thermo Fisher Scientific Inc. (États-Unis), Catalent, Inc (États-Unis), PCI Pharma Services (États-Unis), Almac Group (Royaume-Uni), PAREXEL International Corporation (États-Unis), Bionical Ltd. (Royaume-Uni), Alium Medical Limited (Royaume-Uni), MYODERM (Royaume-Uni), Clinigen Group plc (Royaume-Uni), Ancillare, LP (États-Unis), SIRO Clinpharm (Inde) CLINICAL SUPPLIES MANAGEMENT HOLDINGS, INC. (États-Unis) Biocair (Royaume-Uni) et entre autres.

Méthodologie de recherche : Marché des fournitures pour essais cliniques en Asie-Pacifique

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. Les données du marché sont analysées et estimées à l'aide de modèles statistiques et cohérents du marché. En outre, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. La principale méthodologie de recherche utilisée par l'équipe de recherche DBMR est la triangulation des données, qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). En dehors de cela, les modèles de données comprennent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement de l'entreprise, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse mondiale par rapport aux régions et la part des fournisseurs. Veuillez demander un appel d'analyste en cas de demande de renseignements supplémentaires.


SKU-

Accédez en ligne au rapport sur le premier cloud mondial de veille économique

  • Tableau de bord d'analyse de données interactif
  • Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
  • Accès d'analyste de recherche pour la personnalisation et les requêtes
  • Analyse de la concurrence avec tableau de bord interactif
  • Dernières actualités, mises à jour et analyse des tendances
  • Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Demande de démonstration

Table des matières

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 SERVICES LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTERS FIVE FORCES

5 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET: REGULATORY SCENARIO

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING DEMAND FOR CLINICAL TRIALS WORLDWIDE

6.1.2 INCREASING INCIDENCE OF CHRONIC DISEASES

6.1.3 GOVERNMENT FUNDS IN R&D INVESTMENTS

6.1.4 ADVANCEMENT OF TECHNOLOGY IN CLINICAL TRIALS SUPPLIES

6.2 RESTRAINTS

6.2.1 ADVERSE EFFECTS OF CLINICAL TRIALS

6.2.2 TRANSPORTATION ISSUE IN CLINICAL TRIAL SUPPLIES

6.2.3 HIGH COST ASSOCIATED WITH THE CLINICAL TRIALS

6.3 OPPORTUNITIES

6.3.1 INCREASING NEW DRUG DEVELOPMENT TRIALS IN EMERGING COUNTRIES

6.3.2 INCREASING DEMAND FOR INNOVATIVE SOLUTIONS IN CLINICAL TRIALS SERVICES

6.3.3 EVOLUTION IN SUPPLY CHAIN MANAGEMENT FOR CLINICAL TRIALS

6.4 CHALLENGES

6.4.1 LOWER PROCEDURE TIME OF CLINICAL TRIALS APPROVAL

6.4.2 LACK OF SKILLED PERSON TO OPERATE DEVICES DURING CLINICAL TRIALS

7 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES

7.1 OVERVIEW

7.2 STORAGE

7.3 MANUFACTURING

7.4 PACKAGING AND LABELLING

7.5 DISTRIBUTION

8 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASES

8.1 OVERVIEW

8.2 PHASE III

8.3 PHASE II

8.4 PHASE IV

8.5 PHASE I

9 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE

9.1 OVERVIEW

9.2 ONCOLOGY

9.3 CARDIOVASCULAR DISEASES

9.4 DERMATOLOGY

9.5 METABOLIC DISORDERS

9.6 INFECTIOUS DISEASES

9.7 RESPIRATORY DISEASES

9.8 CNS AND MENTAL DISORDERS

9.9 BLOOD DISORDERS

9.1 OTHERS

10 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET, BY END USER

10.1 OVERVIEW

10.2 CONTRACT RESEARCH ORGANIZATIONS

10.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES

11 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET, BY REGION

11.1 ASIA-PACIFIC

11.1.1 CHINA

11.1.2 JAPAN

11.1.3 INDIA

11.1.4 SOUTH KOREA

11.1.5 AUSTRALIA

11.1.6 THAILAND

11.1.7 MALAYSIA

11.1.8 SINGAPORE

11.1.9 INDONESIA

11.1.10 PHILIPPINES

11.1.11 REST OF ASIA-PACIFIC

12 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET: COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC

13 SWOT ANALYSIS

14 COMPANY PROFILE

14.1 THERMO FISHER SCIENTIFIC INC.

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 COMPANY SHARE ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENT

14.1.5.1 PARTNERSHIP

14.2 ALMAC GROUP

14.2.1 COMPANY SNAPSHOT

14.2.2 COMPANY SHARE ANALYSIS

14.2.3 PRODUCT PORTFOLIO

14.2.4 RECENT DEVELOPMENTS

14.3 CATALENT INC.

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COMPANY SHARE ANALYSIS

14.3.4 SERVICE PORTFOLIO

14.3.5 RECENT DEVELOPMENT

14.3.5.1 SERVICE EXPANSION

14.4 CLINIGEN GROUP PLC

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COMPANY SHARE ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENT

14.4.5.1 PARTNERSHIP

14.5 MOVIANTO

14.5.1 COMPANY SNAPSHOT

14.5.2 COMPANY SHARE ANALYSIS

14.5.3 SERVICE PORTFOLIO

14.5.4 RECENT DEVELOPMENT

14.5.4.1 ACQUISITION

14.6 PCI PHARMA SERVICES

14.6.1 COMPANY SNAPSHOT

14.6.2 SERVICE PORTFOLIO

14.6.3 RECENT DEVELOPMENTS

14.7 SHARP

14.7.1 COMPANY SNAPSHOT

14.7.2 SERVICE PORTFOLIO

14.7.3 RECENT DEVELOPMENT

14.8 ALIUM MEDICAL LIMITED

14.8.1 COMPANY SNAPSHOT

14.8.2 SERVICE PORTFOLIO

14.8.3 RECENT DEVELOPMENT

14.9 ANCILLARE, LP

14.9.1 COMPANY SNAPSHOT

14.9.2 SERVICE PORTFOLIO

14.9.3 RECENT DEVELOPMENT

14.1 BIOCAIR

14.10.1 COMPANY SNAPSHOT

14.10.2 SERVICE PORTFOLIO

14.10.3 RECENT DEVELOPMENTS

14.11 BIONICAL LTD.

14.11.1 COMPANY SNAPSHOT

14.11.2 SERVICE PORTFOLIO

14.11.3 RECENT DEVELOPMENT

14.11.3.1 SERVICE LAUNCH

14.12 CLINICAL SUPPLIES MANAGEMENT HOLDINGS,INC

14.12.1 COMPANY SNAPSHOT

14.12.2 SERVICE PORTFOLIO

14.12.3 RECENT DEVELOPMENT

14.13 KLIFO

14.13.1 COMPANY SNAPSHOT

14.13.2 SERVICE PORTFOLIO

14.13.3 RECENT DEVELOPMENTS

14.13.3.1 ACQUISTION

14.14 MYONEX

14.14.1 COMPANY SNAPSHOT

14.14.2 SERVICE PORTFOLIO

14.14.3 RECENT DEVELOPMENT

14.15 PAREXEL INTERNATIONAL CORPORATION

14.15.1 COMPANY SNAPSHOT

14.15.2 SERVICE PORTFOLIO

14.15.3 RECENT DEVELOPMENT

14.15.3.1 COLLABORATION

14.16 SIRO CLINPHARM PRIVATE LIMITED

14.16.1 COMPANY SNAPSHOT

14.16.2 SERVICE PORTFOLIO

14.16.3 RECENT DEVELOPMENTS

15 QUESTIONNAIRE

16 RELATED REPORTS

Liste des tableaux

TABLE 1 LOCATIONS OF REGISTERED STUDIES

TABLE 2 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 3 ASIA PACIFIC STORAGE IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 ASIA PACIFIC MANUFACTURING IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 ASIA PACIFIC PACKAGING AND LABELLING IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 ASIA PACIFIC DISTRIBUTION IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASE, 2020-2029 (USD MILLION)

TABLE 8 ASIA PACIFIC PHASE III IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 ASIA PACIFIC PHASE II IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 ASIA PACIFIC PHASE IV IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 ASIA PACIFIC PHASE I IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE, 2020-2029 (USD MILLION)

TABLE 13 ASIA PACIFIC ONCOLOGY IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 ASIA PACIFIC CARDIOVASCULAR DISEASES IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 ASIA PACIFIC DERMATOLOGY IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 ASIA PACIFIC METABOLIC DISORDERS IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 ASIA PACIFIC INFECTIOUS DISEASES IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 ASIA PACIFIC RESPIRATORY DISEASES IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 ASIA PACIFIC CNS AND MENTAL DISORDERS IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 ASIA PACIFIC BLOOD DISORDERS IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 ASIA PACIFIC OTHERS IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 23 ASIA PACIFIC CONTRACT RESEARCH ORGANIZATIONS IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 ASIA PACIFIC PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 ASIA-PACIFIC CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 26 ASIA-PACIFIC CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 27 ASIA-PACIFIC CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASE, 2020-2029 (USD MILLION)

TABLE 28 ASIA-PACIFIC CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE, 2020-2029 (USD MILLION)

TABLE 29 ASIA-PACIFIC CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 30 CHINA CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 31 CHINA CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASE, 2020-2029 (USD MILLION)

TABLE 32 CHINA CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE, 2020-2029 (USD MILLION)

TABLE 33 CHINA CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 34 JAPAN CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 35 JAPAN CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASE, 2020-2029 (USD MILLION)

TABLE 36 JAPAN CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE, 2020-2029 (USD MILLION)

TABLE 37 JAPAN CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 38 INDIA CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 39 INDIA CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASE, 2020-2029 (USD MILLION)

TABLE 40 INDIA CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE, 2020-2029 (USD MILLION)

TABLE 41 INDIA CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 42 SOUTH KOREA CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 43 SOUTH KOREA CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASE, 2020-2029 (USD MILLION)

TABLE 44 SOUTH KOREA CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE, 2020-2029 (USD MILLION)

TABLE 45 SOUTH KOREA CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 46 AUSTRALIA CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 47 AUSTRALIA CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASE, 2020-2029 (USD MILLION)

TABLE 48 AUSTRALIA CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE, 2020-2029 (USD MILLION)

TABLE 49 AUSTRALIA CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 50 THAILAND CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 51 THAILAND CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASE, 2020-2029 (USD MILLION)

TABLE 52 THAILAND CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE, 2020-2029 (USD MILLION)

TABLE 53 THAILAND CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 54 MALAYSIA CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 55 MALAYSIA CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASE, 2020-2029 (USD MILLION)

TABLE 56 MALAYSIA CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE, 2020-2029 (USD MILLION)

TABLE 57 MALAYSIA CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 58 SINGAPORE CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 59 SINGAPORE CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASE, 2020-2029 (USD MILLION)

TABLE 60 SINGAPORE CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE, 2020-2029 (USD MILLION)

TABLE 61 SINGAPORE CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 62 INDONESIA CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 63 INDONESIA CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASE, 2020-2029 (USD MILLION)

TABLE 64 INDONESIA CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE, 2020-2029 (USD MILLION)

TABLE 65 INDONESIA CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 66 PHILIPPINES CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 67 PHILIPPINES CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASE, 2020-2029 (USD MILLION)

TABLE 68 PHILIPPINES CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE, 2020-2029 (USD MILLION)

TABLE 69 PHILIPPINES CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 70 REST OF ASIA-PACIFIC CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

Liste des figures

FIGURE 1 ASIA PACIFIC CLINICAL TRIAL SUPLLIES MARKET: SEGMENTATION

FIGURE 2 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET: DATA TRIANGULATION

FIGURE 3 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET: DROC ANALYSIS

FIGURE 4 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA PACIFIC CLINICAL TRIAL SUPLLIES MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET: DBMR MARKET POSITION GRID

FIGURE 8 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET: DBMR VENDOR SHARE ANALYSIS

FIGURE 9 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET: SEGMENTATION

FIGURE 10 NORTH AMERICA IS EXPECTED TO DOMINATE THE ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 11 RISING DEMAND FOR CLINICAL TRIALS WORLDWIDE AND INCREASING INCIDENCES OF DISEASES IS DRIVING THE ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 STORAGE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET IN 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET

FIGURE 14 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET: BY SERVICES, 2021

FIGURE 15 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET: BY SERVICES, 2022-2029 (USD MILLION)

FIGURE 16 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET: BY SERVICES, CAGR (2022-2029)

FIGURE 17 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET: BY SERVICES, LIFELINE CURVE

FIGURE 18 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET: BY CLINICAL PHASE, 2021

FIGURE 19 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET: BY CLINICAL PHASE, 2022-2029 (USD MILLION)

FIGURE 20 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET: BY CLINICAL PHASE, CAGR (2022-2029)

FIGURE 21 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET: BY CLINICAL PHASE, LIFELINE CURVE

FIGURE 22 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET: BY THERAPEUTIC USE, 2021

FIGURE 23 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET: BY THERAPEUTIC USE, 2022-2029 (USD MILLION)

FIGURE 24 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET: BY THERAPEUTIC USE, CAGR (2022-2029)

FIGURE 25 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET: BY THERAPEUTIC USE, LIFELINE CURVE

FIGURE 26 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET: BY END USER, 2021

FIGURE 27 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 28 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET: BY END USER, CAGR (2022-2029)

FIGURE 29 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET: BY END USER, LIFELINE CURVE

FIGURE 30 ASIA-PACIFIC CLINICAL TRIAL SUPPLIES MARKET: SNAPSHOT (2021)

FIGURE 31 ASIA-PACIFIC CLINICAL TRIAL SUPPLIES MARKET: BY COUNTRY (2021)

FIGURE 32 ASIA-PACIFIC CLINICAL TRIAL SUPPLIES MARKET: BY COUNTRY (2022 & 2029)

FIGURE 33 ASIA-PACIFIC CLINICAL TRIAL SUPPLIES MARKET: BY COUNTRY (2021 & 2029)

FIGURE 34 ASIA-PACIFIC CLINICAL TRIAL SUPPLIES MARKET: BY SERVICES (2022-2029)

FIGURE 35 ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET: COMPANY SHARE 2021 (%)

Voir les informations détaillées Right Arrow

Méthodologie de recherche

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.

La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.

Personnalisation disponible

Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.

Questions fréquemment posées

The Asia-Pacific Clinical Trial Supplies Market will be projected to grow at a CAGR of 9.2% during the forecast period of 2022 to 2029.
The Asia-Pacific Clinical Trial Supplies Market is projected at USD 1,021.35 million during the forecast period of 2022 to 2029.
Movianto (U.S.), Sharp (U.S.),Thermo Fisher Scientific Inc.,(U.S.), Catalent, Inc (U.S.), PCI Pharma Services (U.S.), Almac Group (U.K.), PAREXEL International Corporation (U.S.), Bionical Ltd. (U.K.), Alium Medical Limited (U.K.), Myonex (U.K.), Clinigen Group plc (U.K.), Ancillare, LP (U.S.), SIRO Clinpharm (India) CLINICAL SUPPLIES MANAGEMENT HOLDINGS, INC. (U.S.) Biocair (U.K.) are the major players operating in the Asia-Pacific Clinical Trial Supplies Market.
Rising Demand for Clinical Trial Worldwide, Increasing Incidence of Chronic Diseases and Government Funds in R&D Investments are the significant factors flourishing the growth of the Asia-Pacific Clinical Trial Supplies Market.